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ABSTRACT 
 
FOXO1 DIFFERENTIALLY REGULATES  
BOTH NORMAL AND DIABETIC GINGIVAL WOUND HEALING 
 
Hyeran Helen Jeon 
 
Dana T. Graves 
 
We have previously demonstrated that keratinocyte-specific forkhead box O1 (FOXO1) 
deletion interferes with keratinocyte migration in normal skin wounds. However it has an 
opposite effect in diabetic skin wounds, significantly improving the healing response. In 
addition we found that skin epithelium regulates connective tissue healing mediated by 
FOXO1, which is strongly associated with wound angiogenesis in our microarray results. 
However, a role for keratinocytes in this complex process has yet to be investigated. To 
this end, we investigated possible involvement of gingival keratinocytes in connective 
tissue healing under both normal and diabetic conditions. We found that keratinocyte-
specific FOXO1 deletion interfered with normal gingival connective tissue healing by 
decreasing granulation tissue formation and angiogenesis, which were mediated by 
vascular endothelial growth factor A (VEGF-A). In particular this is the first evidence that 
avascular epithelium regulates angiogenesis involving the VEGF-A secretion mediated 
by FOXO1. Furthermore, we investigated the possible role of epithelial to mesenchymal 
transition (EMT) during wound healing using the lineage tracing in transgenic mice. But 
we did not find any keratinocyte-specific reporter activity in the connective tissue 
indicating that there was no apparent trans-differentiation of keratinocytes into typical 
fibroblasts or myofibroblasts during wound healing. These results establish an important 
role of epithelial cells in accelerating wound angiogenesis and connective tissue healing 
through a FOXO1-dependent mechanism. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Wound Healing, Diabetes and Angiogenesis 
Wound healing is a dynamic interactive process that begins at the moment of wounding 
and involves soluble mediators, many cell types, and extracellular matrices (5-7). The 
healing of oral wounds proceeds through similar stages as that of skin wounds including 
three phases: 1) inflammatory phase, 2) proliferative phase, and 3) maturation phase 
(8). A number of cell subsets contribute to healing, including keratinocytes, fibroblasts, 
endothelial cells and inflammatory cells. The activity of these cells is regulated by 
cytokines acting in both autocrine and paracrine fashion to bring about efficient healing 
(9). The goal of the inflammatory phase is to obtain hemostasis and to provide an influx 
of neutrophils and macrophages into the wound bed in a milieu of cytokines and growth 
factors. At the end of the inflammatory phase apoptosis of inflammatory cells appears 
concurrently with re-epithelialization of the wound and may be a signal of healing at that 
site in the wound (10). The second phase, the proliferative phase, is characterized by 
the granulation tissue formation, angiogenesis, deposition of new extracellular matrix 
(ECM), and re-epithelialization. Although granulation is classically assigned to the 
proliferative stage, angiogenesis is initiated immediately upon wounding and is mediated 
throughout the entire wound healing process. In order to manufacture the extracellular 
matrix fibroblasts require oxygen and nutrients so there is a requirement for 
angiogenesis (11). The third phase, the maturation phase, involves wound contraction 
and remodeling. Collagen is realigned along tension lines and cells that are no longer 
needed are removed by programmed cell death or apoptosis.  
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Diabetes has a major effect on wound healing. It is a chronic disease characterized by 
elevated blood sugar levels resulting from either lack of insulin production or resistance 
to insulin (12). It is one of the most challenging health problems of the 21st century. 
Some 382 million people worldwide (8.3% of adults) are estimated to have diabetes (13). 
If these trends continue, by 2035, some 592 million people, or one adult in 10, will have 
diabetes. The largest increases will take place in the regions where developing 
economies are predominant. In addition, diabetes imposes a large economic burden on 
individuals and families, national health systems, and countries. Health spending on 
diabetes accounted for 10.8% of total health expenditure worldwide in 2013. There are 
numbers of complications caused by diabetes, including increased heart disease, stroke, 
blindness, kidney failure, and delayed wound healing (14). Diabetes affects the oral 
cavity by increasing the prevalence of caries, gingivitis, periodontal disease, implantitis, 
fibromas, and traumatic ulcers (15). A number of factors may contribute to impaired 
healing in diabetics, such as decreased or impaired growth factor production (16-18), 
angiogenic response (18, 19), macrophage function (20), collagen accumulation, 
epidermal barrier function, quantity of granulation tissue (18), keratinocyte and fibroblast 
migration and proliferation, number of epidermal nerves (21), bone healing, and balance 
between the accumulation of ECM components and their remodeling by matrix 
metalloproteinases (MMPs) (22) (Fig. 1). One of the major cellular components of wound 
granulation tissue relevant to healing and angiogenesis is macrophages (23, 24). Wound 
macrophages have been established as key players in the maintenance of tissue 
homeostasis through tissue remodeling and repair via the release of mediators at the 
wound site (25). In support of this view, suppressed recruitment of macrophages into 
granulation tissue impairs wound healing (26, 27). Decreased numbers of macrophages 
and insufficient macrophage activation contribute to the impaired healing of diabetic 
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wounds (20). Increased fibroblast apoptosis has been proposed to be a mechanism for 
diabetes-impaired dermal wound healing (28-30). Patients with diabetes are 
characterized by a reduction in angiogenesis, which is an important part of the 
proliferative phase of healing. Limited penetration of new blood vessels into the wound 
would restrict entry of inflammatory cells, and high amounts of distinct angiogenic factors 
	  
Figure 1. Mechanisms of wound healing in healthy people versus people with diabetes (31) 
In healthy individuals (left), the acute wound healing process is guided through multiple signals 
released by keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets. During 
wound-induced hypoxia, VEGF released by keratinocytes, macrophages and fibroblasts induces 
the phosphorylation and activation of Endothelial Nitric Oxide Synthase (eNOS) in the bone 
marrow, resulting in an increase in NO levels, which triggers the mobilization of bone marrow 
EPCs to the circulation. On the contrary, in people with diabetes (right) keratinocytes show less 
migration and incomplete differentiation. Fibroblasts demonstrate the decreased migration and 
proliferation. Also, the amount of VEGF released by several different cell types is reduced, 
resulting in impaired eNOS activation in bone marrow, which directly limits endothelial progenitor 
cells (EPC) homing. Therefore it impairs wound healing. 
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produced by immune cells are limited (32). Factors that play a decisive role in diabetes-
associated wound healing disorders comprise augmented inflammatory responses, 
impaired granulation tissue formation, reduced growth factors and a disturbed 
angiogenesis (13). In particular, hyperglycemia-related microvascular pathology is 
thought to be a critical contributor to impaired diabetic healing (33). Hyperglycemia can 
affect endothelial function via several major mechanisms, including toxic effects on 
endothelial cells via nitric oxide, oxidative stress and inflammation (34, 35), and 
accumulation of advanced glycation end products (AGEs) that results in altered 
extracellular matrix and disrupted angiogenic growth factor signaling (36, 37). In vitro 
studies in high glucose culture conditions demonstrated increased endothelial apoptosis 
(38, 39); impaired proliferation, adhesion, and tube formation (40, 41); and changes in 
cytokine production (16). 
Streptozotocin (STZ) is most widely used to induce experimental diabetes in rodents 
because of its simplicity and reproducibility (42). STZ (2-deoxy-2-(3-methyl-3-
nitrosourea)-1-D-glucopyranose) is a broad-spectrum antibiotic which is produced by 
Streptomyces achromogenes. The diabetogenic effect of STZ was first reported in 1963 
by Rakieten et al. after injection of a single intravenous dose in rats and dogs (43). STZ 
is similar enough to glucose (Glu) and N-acetyl glucosamine (GlcNAc) (Fig. 2) to be 
transported into the pancreatic β cells by the glucose transport protein GLUT2, but is not 
recognized by the other glucose transporters. This explains its relative toxicity to β cells, 
since these cells have relatively high levels of GLUT2 (44, 45). Once it is taken it causes 
β-cell death by DNA fragmentation due to the nitrosourea moiety. Three major pathways 
associated with cell death are: (i) methylation of DNA by the formation of carbonium ion 
(CH3+) resulting in the activation of the nuclear enzyme poly ADP-ribose synthetase as 
part of the cell repair mechanism and therefore NAD+ depletion; (ii) free radical 
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generation as hydrogen peroxide and (iii) nitric oxide production (46, 47). The toxic 
effects of STZ are not restricted to pancreatic β-cells. STZ also causes renal, cardiac 
and adipose tissue damage and increases oxidative stress, inflammation and endothelial 
dysfunction (48). Moreover, several studies have described immune-modifying effects of 
STZ both in vitro and in vivo (49-51). 
 
 
Wound angiogenesis is critical to wound healing. Angiogenesis is initiated upon 
wounding by multiple molecular signals, including hemostatic factors, inflammation, 
cytokine growth factors, and cell-matrix interactions. Initially, there is no vascular supply 
to the wound center and the appearance of new viable tissue is limited to wound 
margins that are in contact with uninjured tissue through direct contact with uninjured 
blood vessels and through the process of short-distance diffusion through the uninjured 
interstitium. Under normal conditions, a tissue or tumor cannot grow beyond 1 to 2 mm 
in diameter without neovascularization. This distance is defined by limits in the diffusion 
of oxygen and metabolites, such as glucose and amino acids (52). The vascular 
Figure 2. Chemical structures of (A) glucose, (B) N-acetyl glucosamine and (C) streptozotocin 
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component depends upon angiogenesis, in which new vessels appear as early as d 3 
after wounding (53). The formation of new blood vessels in the developing acute 
granulation tissue (angiogenesis) occurs by a budding or sprouting mechanism from 
intact vessels at the wound borders. The development of vascular outgrowths requires 
endothelial cell proliferation. Numerous tissue growth factors such as vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) play central 
regulatory roles in neovascularization and subsequent tissue repair (54). Macrophages 
also appear to be necessary for wound neovascularization to occur, especially along 
wounded tissue oxygen gradients (55). As collagen accumulates in the granulation 
tissue to produce scar, the density of blood vessels diminishes (56). New capillaries 
proliferate via a cascade of biological events to form granulation tissue in the wound 
bed. Injured tissue releases growth factors that bind to their receptors on endothelial 
cells, activating signal transduction pathways and stimulating endothelial proliferation, 
migration, and vascular tube formation. Bone marrow derived endothelial progenitor cells 
are mobilized and become incorporated into new blood vessels. Stabilization of the 
vasculature occurs through the recruitment of smooth muscle cells and pericytes (Fig. 
3). Several evidences implicate VEGF as a significant factor in wound healing 
immediately after injury (53, 57). Maximal activity occurs during a period approximately 3 
to 7 d after injury. Once the wound is granulated, angiogenesis ceases and blood 
vessels decline as endothelial cells undergo apoptosis. 
Defects in the angiogenesis delay healing and these are evident in chronic wounds. In 
general, the process of angiogenesis is believed to be controlled by changes in the 
levels of proangiogenic and antiangiogenic molecules present within the 
microenvironment surrounding the vasculature (1). Many proangiogenic and 
antiangiogenic mediators have been identified (Table 1). Vascular endothelial growth  
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Figure 3. The Angiogenesis Cascade of Events and Multiple targets Injured tissues release 
growth factors that bind to their receptors on endothelial cells, activating signal transduction 
pathways and stimulating endothelial proliferation, migration, and vascular tube formation. Bone 
marrow derived endothelial stem cells are mobilized and become incorporated into new blood 
vessels. Stabilization of the vasculature occurs through the recruitment of smooth muscle cells 
and pericytes. 
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Table 1. Molecular Regulators of Angiogenesis (Source: The Angiogenesis Foundation) 
 
Angiogenic Stimulators 
 
 
Angiogenin 
Angiopoietin-1 
Del-1 
Fibroblast growth factors: acidic (aFGF) and 
basic (bFGF) 
Follistatin 
Granulocyte colony-stimulating factor (G-
CSF) 
Hepatocyte growth factor (HGF) /scatter 
factor (SF) 
Interleukin-8 (IL-8) 
Leptin 
Midkine 
Placental growth factor 
Platelet-derived endothelial cell growth 
factor (PD-ECGF) 
Platelet-derived growth factor-BB (PDGF-
BB) 
Pleiotrophin (PTN) 
Progranulin 
Proliferin 
Transforming growth factor-alpha (TGF-
alpha) 
Transforming growth factor-beta (TGF-beta) 
Tumor necrosis factor-alpha (TNF-alpha) 
Vascular endothelial growth factor 
(VEGF)/vascular permeability factor (VPF) 
 
 
Angiogenesis Inhibitors 
 
 
Angioarrestin 
Angiostatin (plasminogen fragment) 
Antiangiogenic antithrombin III 
Arrestin 
Chondromodulin 
Canstatin 
Cartilage-derived inhibitor (CDI) 
CD59 complement fragment 
Endostatin (collagen XVIII fragment) 
Endorepellin 
Fibronectin fragment 
Fibronectin fragment (Anastellin) 
Gro-beta 
Heparinases 
Heparin hexasaccharide fragment 
Human chorionic gonadotropin (hCG) 
Interferon alphagamma 
Interferon inducible protein (IP-10) 
Interleukin-12 
Kringle 5 (plasminogen fragment) 
Metalloproteinase inhibitors (TIMPs) 
2-Methoxyestradiol 
PEX 
Pigment epithelium derived factor (PEDF) 
Placental ribonuclease inhibitor 
Plasminogen activator inhibitor 
Platelet factor-4 (PF4) 
Prolactin 16kD fragment 
Proliferin-related protein (PRP) 
Prothrombin kringle 2 
Retinoids 
Soluble Fms-like tyrosine kinase-1 (S-Flt-1) 
Targeting fibronectin-binding integrins 
Tetrahydrocortisol-S 
Thrombospondin-1 (TSP-1) and -2 
Transforming growth factor-beta (TGF-b) 
Troponin I 
Tumstatin 
Vasculostatin 
Vasostatin (calreticulin fragment) 
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factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor and 
placental growth factor (PlGF) are proteins that stimulate angiogenesis whereas 
angiostatin (a fragment of plasminogen), endostatin (a fragment of collagen XVIII) and 
thrombospondin-1 are examples of angiogenesis inhibitors. The maintenance of vessels 
in a quiescent state is thought to occur when the level of antiangiogenic signals outweigh 
proangiogenic signals; however, periods of active angiogenesis occur when endothelial 
cells sense a shift in the balance of these mediators, with proangiogenic signals 
predominating over antiangiogenic signals. The angiogenic switch concept was 
proposed by Folkman and Hanahan, who first used it to describe the regulation of tumor 
angiogenesis (58). These events are stimulated in part by a number of mitogens and 
chemotactic factors. The soluble factors shown to be mitogenic for endothelial cells in 
vitro and angiogenic in vivo include different members of the fibroblast growth factor 
family, transforming growth factor-α (TGF-α), epidermal growth factor (EGF) (5) and 
platelet-derived growth factor BB (6). Furthermore, transforming growth factor-β (TGF-β) 
and tumor necrosis factor-α (TNF-α) have been shown to be angiogenic in vivo, although 
they inhibit endothelial cell growth in vitro (7-11). Thus, they may be indirectly angiogenic 
under certain conditions. The vascular endothelial growth factor (VEGF) is the most 
potent and specific vascular growth factor. VEGF family comprises in mammals five 
members: VEGF-A, placental growth factor (PIGF), VEGF-B, VEGF-C and VEGF-D. The 
latter ones were discovered later than VEGF-A and, before their discovery, VEGF-A was 
termed VEGF. It is a soluble protein secreted by a wide variety of cell types. The 
inhibition of VEGF by antibody has been shown to inhibit angiogenesis (59-61). VEGF-A 
levels are regulated through transcriptional control and mRNA stability (62). Four 
different human isoforms of VEGF-A including VEGF-A121, VEGF-A165, VEGF-A189, and 
VEGF-A206, have been isolated from various sources and arise by alternative splicing of 
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mRNA (12). The most abundant isoform found in human tissue is VEGF-A165. Whereas 
all VEGF-A isoforms seem to have similar biological activities, only VEGF-A121 and 
VEGF-A165 are secreted in soluble form, whereas the higher-molecular-weight forms 
apparently remain cell associated (63). VEGF-A plays a pivotal role during the 
angiogenic response in tissue repair by regulating vascular permeability, the influx of 
inflammatory cells into the site of injury, migration and proliferation of pre-existing 
endothelial cells and the recruitment of marrow-derived endothelial progenitor cells to 
the local wound site (4, 19, 57, 64, 65). In skin major sources of VEGF-A are epidermal 
keratinocytes, macrophages, endothelial cells, fibroblasts and mast cells (1, 66-68). 
VEGF-A is up-regulated during the early days of healing, when capillary growth is 
maximal. Delayed wound closure and reduced vessel density have been reported in 
mice lacking VEGF-A in keratinocytes (65). 
Brown et al. demonstrated expression of VEGF 
mRNA in proliferating keratinocytes of the newly 
formed epithelium during wound healing (4) (Fig. 
4). In contrast, expression of one of the receptors 
for VEGF-A (flt-1) was found to be up-regulated 
in the sprouting blood vessels at the wound edge 
(19) and in endothelial cells of the granulation 
tissue (20). These findings suggest that keratinocyte-derived VEGF-A stimulates 
angiogenesis during wound healing in a paracrine manner. Detmar et al. characterized 
the effects of several cytokines and growth factors on the expression and secretion of 
vascular permeability factor (VPF)/VEGF mRNA and protein by cultured human 
epidermal keratinocytes, as well as the effect of VPF/VEGF on the growth of cultured 
human dermal microvascular endothelial cells (69). These results suggest that the 
Figure 4. In situ expression of VEGF 
mRNA in healing rat. Epidermal 
labeling was maximal on days 2-3 (4). 
	  
	  
11	  
avascular epidermis has the capacity to regulate dermal angiogenesis and 
microvascular permeability by a paracrine mechanism involving the secretion of 
VPF/VEGF.  
VEGF-A transcription and secretion are elevated in partial (4) and full-thickness skin 
wounds (70, 71). In partial thickness wounds, keratinocytes at the wound edge express 
elevated VEGF-A as early as 1 d after injury and eventually migrate to cover the defect. 
Epidermal labeling for VEGF-A mRNA reaches a peak after 2–3 d, coincident with a 
peak in vascular permeability, and levels remain elevated until epidermal coverage is 
complete. Similarly maximal VEGF-A mRNA is found between 3 and 7 d after full-
thickness wounding during the period of granulation tissue formation (70). The time 
course of VEGF-A expression provides insight into the progression of wound healing. 
During the proliferative phase of repair occurring approximately 3 to 7 d post-wounding 
capillary growth and differentiation are at a maximum. During this period, VEGF-A is up-
regulated to promote the early stages of angiogenesis (i.e., vascular dilation, 
permeability, migration, and proliferation) (57). Antibody neutralization of VEGF-A 
diminishes the chemotactic and angiogenic properties of wound fluid, thus revealing 
further evidence for the importance of VEGF-A in wound repair (57). Additionally, 
wounds of streptozotocin-induced diabetic mice demonstrate diminished synthesis of 
several growth factors including VEGF-A (71). 
To date, the majority of the effects of VEGF-A during wound repair have been attributed 
to its proangiogenic activity (1) (Fig. 5); however, recent studies have indicated that in 
addition to vascular endothelial cells, other cells such as keratinocytes and 
macrophages express VEGFRs and can respond directly to VEGF-A. VEGF-A likely 
promotes collagen deposition and epithelialization as well (53). Traditionally, VEGF-A 
produced by epidermal keratinocytes was thought to act in a paracrine manner, 
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stimulating endothelial cells within the granulation tissue. However, functional VEGFRs 
have been recently identified on keratinocytes (72-75), which suggests the possibility of 
autocrine VEGF-A signaling in keratinocytes as well as direct effects of VEGF-A derived 
from other cellular sources on keratinocytes. Direct effects of VEGF-A on keratinocytes 
have been described in vitro using cultured primary human keratinocytes (72) and 
primary mouse keratinocytes (73). Those studies suggested possible roles for VEGF-A 
in the regulation of keratinocyte proliferation, migration and survival (72, 73, 75-77). In 
addition to keratinocytes, myeloid cells (monocytes and macrophages) are another 
important cell type known to respond to VEGF-A during wound healing (1). Monocytes 
and macrophages express VEGFR-1 and VEGF-A has been shown to increase the 
migration of these cells in vitro through VEGFR-1 (78-80). A higher density of 
macrophages has been reported in wounds from VEGF-A transgenic mice (81). 
 
 
 
 
Figure 4  
Figure'4'
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Figure 5. Cellular sources and actions of VEGF during wound healing (1) 
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1.2 Epithelial-Mesenchymal Transition (EMT) in Wound Healing 
 
Epithelial to mesenchymal transition (EMT), originally identified as an essential 
differentiation and/or morphogenetic process during embryogenesis, may contribute to 
wound healing, tissue remodeling, fibrosis, and metastatic malignancies (82). Elizabeth 
Hay first described an “epithelial-mesenchymal transformation” using a model of chick 
primitive streak formation (83). In the intervening time, the term “transformation” has 
been replaced with “transition,” reflecting in part the reversibility of the process and the 
fact that it is distinct from neoplastic transformation (84). Three distinct manifestations of 
EMT have been proposed based on stages of development and associated biomarkers; 
1) embryogenesis and organ development (Type I), 2) wound healing and organ fibrosis 
in mature tissue (Type II), and 3) tumorigenesis and cancer metastasis (Type III) (Fig. 6). 
EMT is a trans-differentiation process by which epithelial cells lose their epithelial 
characteristics and acquire a mesenchymal phenotype and is characterized by changes 
in cell morphology, and disruption of tight junctions and adherent junctions (85) (Fig. 7). 
Down-regulation of E-cadherin is considered a key step in EMT (Fig. 8). A growing 
number of transcriptional molecules have been found to be involved in the EMT process 
(Table 2) (86). Among them, ectopic expression of Snail has been reported to suppress 
E-cadherin expression, leading to a full EMT phenotype, whereas silencing of Snail 
expression reverses this process (87). The acquired mesenchymal phenotype is 
characterized by expression of cytoskeletal proteins such as α-smooth muscle actin (α-
SMA) and vimentin, as well as matrix metalloproteinases (MMPs). As a result of these 
phenotypic changes, epithelial cells are released from the surrounding tissue and 
become migratory and invasive.  
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Figure 6. Different types of Epithelial to mesenchymal transition (88); (A) embryogenesis 
and organ development (Type I), (B) wound healing and organ fibrosis in mature tissue (Type II), 
and (C) tumorigenesis and cancer metastasis (Type III)  
 
 
 
Figure 7. Epithelial to mesenchymal transition (EMT) (88). An EMT involves a functional 
transition of polarized epithelial cells into mobile and ECM component-secreting mesenchymal 
cells.  
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More recently, EMT-like processes have been 
described during tissue repair (89). Transforming 
growth factor β (TGF-β) is the most potent inducer of 
EMT (90) as well as an essential factor during normal 
wound healing. Transforming growth factor β (TGF-β) 
signaling at the wound site has been implicated in re-
epithelialization, inflammatory cells infiltration, wound 
contraction, extracellular matrix deposition and 
remodeling. Successful wound healing is a complex 
process involving cells of the epidermis, dermis, 
vasculature, and the immune system (91). Two distinct 
cellular mechanisms directly contribute to the closure 
of skin wounds: keratinocyte-driven re-epithelialization 
and fibroblast-mediated contraction of the newly formed connective tissue bed beneath 
the wound site, pulling the edges of the wound closer together (92). During re-
epithelialization, migrating keratinocytes undergo numerous phenotypic and functional 
alterations reminiscent of epithelial–mesenchymal transformation, including disruption of 
desmosomes and hemidesmosomes, alterations in the actin-based cytoskeleton, 
retraction of intermediate filaments and loss of cell polarity. Epithelial cells migrate from 
the	  edges of the wound very soon after the initial insult until a complete sheet of cells 
covers the wound and attaches to the matrix below. In wounds that are primarily closed, 
this phase can be completed within 24 hours. Changes in cytokine concentration result 
in epithelial cells switching from a motile phenotype to a proliferative one in order to  
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  Figure 8. The Epithelial Phenotype. Polarized epithelial        
cells are typified by tight junctions, adherens junctions, 
desmosomes, and gap junctions. (3) 
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Table 2. Epithelial to Mesenchymal Transition Markers (86)  
Proteins that increase in abundance	  
N-cadherin 
Vimentin 
Fibronectin 
Snail1 (Snail) 
Snail2 (Slug) 
Twist 
Goosecoid 
FOXC2 
Sox10 
MMP-2 
MMP-3 
MMP-9 
Integrin αvβ6 
 
Proteins that decrease in abundance 
E-cadherin 
Desmoplakin 
Cytokeratin 
Occludin 
 
Proteins whose activity increases 
ILK 
GSK-3β 
Rho 
 
Proteins that accumulate in the nucleus 
β-catenin 
Smad-2/3 
NF-κβ 
Snail1 (Snail) 
Snail2 (Slug) 
Twist 
 
In vitro functional markers 
Increased migration 
Increased invasion 
Increased scattering 
Elongation of cell shape 
Resistance to anoikis 
17	  
	  
repopulate epithelial cell levels and complete wound repair (93). In wounds that heal by 
secondary intention, the area lacking epithelial cells can be large and the wound must 
contract significantly before epithelialization can be completed. Wound contraction 
process is performed by myofibroblasts activated by TGF-β (70). The sources of 
myofibroblasts in a healing wound are numerous. Emerging evidence suggests that 
epithelial cells are also an important source of myofibroblasts in fibrosis and cancer (94). 
But, its role during wound healing is ambiguous. Several studies have examined Slug 
expression in skin injury models to provide evidence for an EMT-like process in 
cutaneous wound healing (95, 96). Savagner et al. analyzed the expression of Snai2 
during the wound healing by in situ hybridization. Snai2 expression was elevated in 
keratinocytes bordering cutaneous wounds in mice in vivo, in keratinocytes migrating 
from mouse skin explants ex vivo, and in human keratinocytes at wound margins in vitro. 
Overexpression of Snai2 in keratinocytes caused increased cell spreading and 
desmosomal disruption in vivo and accelerated in vitro wound healing, suggesting a 
critical role for Snai2 in epithelial keratinocyte migration and wound healing. 
Furthermore, in Slug-null mice, a 1.7-fold decrease in re-epithelialization was seen in an 
excisional wound model. These studies indicate that an EMT-like process might occur in 
the re-epithelialization process of wound healing.  
To date, several studies supporting EMT during wound healing have focused on re-
epithelialization through keratinocyte migration. On the other hand, studies 
demonstrating EMT trans-differentiation from keratinocytes into myofibroblasts during 
wound healing are rare. Yan et al. characterized the EMT-like features in acute and 
fibrotic wounds in human skin (89). In tissue staining, they rarely noticed the co-
localization of both E-cadherin and vimentin/fibroblast-specific protein 1 (FSP-1) cells in 
epithelial layers. This is understandable because gain of mesenchymal and loss of 
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epithelial markers occurs simultaneously, leaving very little window to trap the transition 
process. However, such dynamic transition has been recapitulated in vitro. With co-
localization stain method they did not observe trans-differentiation of human 
keratinocytes into myofibroblasts. Trans-differentiation is ideally demonstrated by 
lineage tracing using transgenic mice in which epithelial cells have been “permanently” 
marked.  
Among the major proteins exclusive to epithelial tissues are keratins, a family of >20 
proteins whose members are differentially expressed in a tissue-, differentiation-, and 
developmental- specific fashion (97). Based on sequence homologies, these proteins 
can be subdivided into two distinct groups: type I keratins are smaller (40-56.5 kDa) and 
acidic (pKi = 4.5-5.5), and type II keratins are larger (53-67 kDa) and more basic (pKi  = 
5.5-7.5) (98). Type I and type II keratins are expressed as specific pairs. Keratin 14 (K14) 
and its partner K5 are the major proteins expressed by the mitotically active cells of the 
epidermis and its appendages (99, 100) and the genes encoding these keratins are 
abundantly transcribed in cultured human keratinocytes (101). For these reasons, the 
K14 and K5 promoters are especially attractive candidates for use in studies of 
keratinocytes. For our study we utilized the Cre-loxP recombination system for the 
introduction of a spatiotemporal gene ablation with human keratin 14 (K14) promoter. 
The system generally requires cross mating of two lines of genetically manipulated mice 
(Fig. 9). One line of mice carries alleles with a gene of interest flanked by two identically 
orientated loxP sites. The other line contains a Cre transgene in which the expression of 
Cre is controlled by a defined promoter. Recombination between the two loxP sites in 
the mated mice results in the catalysis of a deletion of the region flanked by the loxP 
sites; this is dependent on Cre transgene expression.  
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To study EMT we examined transgenic mice expressing Cre and a fusion protein 
between Cre recombinase and the tamoxifen responsive hormone-binding domain of the 
estrogen receptor (CreER). Expression of the fusion protein was under the control of the 
human keratin 14 (K14) promoter. The CreER recombinases are inactive, but can be 
activated by the synthetic estrogen receptor ligand 4-hydroxytamoxifen (OHT), therefore 
allowing for external temporal control of Cre activity. By combining tissue-specific 
expression of a CreER recombinase with its tamoxifen-dependent activity, the excision 
of floxed chromosomal DNA can be controlled in a time- and tissue-specific manner. In 
CRE-LOX                                       
TISSUE-SPECIFIC KNOCKOUT 
X 
Homozygous FOXO1 “floxed” 
mouse 
FOXO1 LoxP LoxP 
FOXO1 LoxP LoxP 
Keratin 14-specific cre transgene 
FOXO1 
FOXO1 
KRT14 cre 
Cre-Lox Mouse:  
Heterozygous for FOXO1 
knockout after 1st generation   
FOXO1 
KRT14 cre 
FOXO1 LoxP LoxP 
25% Homozygous for FOXO1 
knockout (2nd generation) FOXO1 
LoxP LoxP 
FOXO1 LoxP LoxP 
KRT14 cre 
XHomozygous FOXO1 “floxed” mouse 
Figure 9. Cre-loxP recombination system 
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order to label the fluorescence to keratinocyte, we crossed K14CreER transgenic mice 
with ROSA26 Cre reporter mouse (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J). 
TdTomato is expressed following Cre-mediated recombination with tamoxifen 
administration. To our knowledge, this model is the first to assess the role of EMT as the 
mechanism of trans-differentiation of keratinocytes into typical myofibroblasts during 
wound healing. 
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1.3 FOXO1, Wound healing and Angiogenesis 
 
The forkhead boxO (FOXO) transcription factors represent a subclass of a large family 
of forkhead proteins characterized by the presence of a winged-helix DNA binding 
domain called Forkhead box (102). In mammals this subclass comprises four members: 
FOXO1 (or FKHR), FOXO3 (or FKHRL1), FOXO4 (also called AFX) and FOXO6 (103). 
The four mammalian isoforms may have both distinct and overlapping functions and 
compensation of one member by another may mask the function of individual FOXOs. 
FOXO1, 3 and 4 are ubiquitously expressed and relatively abundant in bone and bone 
cells. FOXO6 expression is confined to the brain (104). FOXOs are master signaling 
integrators that translate environmental stimuli, like hormonal changes, inflammation, 
and oxidative stress, into dynamic gene expression programs involved in many 
physiological and pathological processes (Fig. 10). Among the many biological functions 
they serve, FOXO proteins are known best for three defining properties: survival, by 
means of resistance to oxidative stress; glucose metabolism, a property specific to 
FOXO1; and suppression of tumorigenesis, a property also mainly regulated by FOXO1 
(105). Balancing the multiple avenues of FOXO activity are several opposing signaling 
pathways that regulate their localization to the nucleus, where they are active (106-108). 
Among them FOXO1 is particularly noteworthy in that it regulates the most diverse array 
of the FOXO’s known biological activities, including organ growth, insulin action, 
tumorigenesis, and angiogenesis. It is a main target of insulin signaling and regulates 
metabolic homeostasis and organismal survival at many different levels.  
FOXO proteins are deactivated by the insulin/PI3K/Akt signaling pathway (2). A major 
form of regulation is Akt-mediated phosphorylation of FOXO in response to insulin or 
growth factors. Phosphorylation at three conserved residues results in the export of  
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FOXO factors from the nucleus to the cytoplasm, thereby inhibiting FOXO-dependent 
transcription. FOXO proteins are also phosphorylated by other protein kinases, including 
JNK or the mammalian ortholog of the St20-like protein kinase (Mst1), which 
phosphorylate FOXO under conditions of oxidative stress. This phosphorylation leads to 
translocation of FOXO into the nucleus, thus opposing Akt’s action. In addition to being 
post-translationally modified by phosphorylation, FOXO proteins also bind to co-activator 
or co-repressor complexes and become acetylated or deacetylated.  
Recent evidences indicate that FOXO1 plays a critical role in wound healing. Mori et al. 
performed immunohistochemistry (IHC) analysis to determine which cells express 
Figure 10. In the absence of insulin or growth factors, FOXO transcription 
factors are located in the nucleus, where they specify target gene expression 
(2). 
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FOXO1 protein during skin wound healing (109). By only 1 day after injury, FOXO1 was 
markedly present in the leading edge and basal layer of keratinocytes and hair follicles 
and in recruited neutrophils. Seven days after injury FOXO1 was present in 
macrophages, fibroblasts and endothelial cells at the wound site. Ponugoti et al. 
demonstrated that FOXO1 promotes wound healing through the up-regulation of TGF-β1 
and prevention of oxidative stress in normal wounds (110). Lineage-specific FOXO1 
deletion in keratinocytes interfered with wound healing and keratinocyte migration in 
normal skin and mucosal wounds (110-113). Surprisingly, the same deletion of FOXO1    
in diabetic wounds had the opposite effect, significantly improving the healing response 
(111-113). In high glucose, FOXO1 enhanced expression of serpin peptidase inhibitor, 
clade B (ovalbumin), member 2 (SERPINB2), and chemokine (C-C motif) ligand 20 
(CCL20). The impact of high glucose on keratinocyte migration was rescued by silencing 
FOXO1, by reducing SERPINB2 or CCL20, or by insulin treatment (111). Thus, FOXO1 
expression can positively or negatively modulate keratinocyte migration and wound 
healing by its differential effect on downstream targets modulated by factors present in 
diabetic but not normoglycemic healing. In addition FOXO1 expression in vascular cells 
is necessary for vascular cell development as well as for the biological response to 
cellular mediators. Mice homozygous for a Foxo1–/– allele, but not Foxo3a–/– or Foxo4–/– 
mice, die during embryogenesis from defects in vascular development (16, 17). 
Endothelial cell colonies in Foxo1-deficient mice fail to respond to vascular endothelial 
growth factor in a manner similar to wild-type endothelial cells (114). Although these 
studies suggest an essential role of FOXO1 in the formation and maturation of the 
nascent vasculature, relatively little is known about the function and significance of the 
distinct FOXO family members for the angiogenic activity of endothelial cells and 
postnatal vessel formation (115). In addition our microarray results show that those 
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genes selectively decreased by FOXO1 knockdown in normal human epidermal 
keratinocytes (NHEK) are most strongly associated with angiogenesis, suggesting that 
FOXO1 activation in keratinocytes may have a strong relationship with wound 
angiogenesis (Table 3). 
 
 
 
 
 
Gene name Fold change by FOXO1 knockdown 
Interleukin 18 -1.91197 
Vascular endothelial growth factor C -1.82767 
Angiopoietin-like 4 -1.63326 
Vascular endothelial growth factor A -1.61825 
Cysteine-rich, angiogenic inducer, 61 -1.53097 
Connective tissue growth factor -1.49486 
Hypoxia inducible factor 1, alpha subunit -1.38889 
Fibroblast growth factor 2 (basic) -1.35659 
 
 
 
 
 
 
 
 
Table 3. Genes down-regulated by FOXO1 knockdown and related to angiogenesis 
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1.4 Hypothesis 
 
Diabetes is a significant health concern in the United States, where 25.8 million people 
(8.3% of the population) have diabetes. Impaired wound healing is a major complication 
of diabetes. Factors that play a decisive role in diabetes-associated wound healing 
disorders comprise augmented inflammatory responses, impaired granulation tissue 
formation, reduced growth factors and a disturbed angiogenesis. 
Wound angiogenesis is pivotal to wound healing and results from multiple signals acting 
on endothelial cells (ECs). VEGF is one of the most potent angiogenic mediators, with 
keratinocytes and macrophages being the major producers. As another possible factor 
that may affect connective tissue healing, epithelial-mesenchymal transition (EMT) is 
recognized as a process that contributes to embryogenesis, tissue remodeling, fibrosis, 
and metastatic malignancies. It is an orchestrated series of events during which 
epithelial cells lose many of their epithelial specific characteristics and acquire features 
typical of mesenchymal cells. Although this concept has been mentioned sporadically in 
the literature as an important aspect of wound healing, there is no in vivo evidence that 
EMT plays a direct role in oral repair processes.  
Forkhead box O1 (FOXO1), which belongs to a large family of forkhead transcription 
factors, participates in a wide range of cellular processes, including cell cycle arrest, 
DNA repair, apoptosis, oxidative stress resistance, angiogenesis and glucose 
metabolism. Recent studies from our lab showed that lineage-specific FOXO1 deletion in 
keratinocytes interfered with re-epithelialization in normal skin and mucosal wounds. 
Surprisingly, the same deletion of FOXO1 in diabetic wounds had the opposite effect, 
significantly improving re-epithelialization. As keratinocytes are a major source of growth 
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factors such as VEGF, FOXO1 activity in keratinocytes may affect connective tissue 
healing, but this important question has not been previously investigated in vivo.  
 
Based on these findings, my central hypothesis is that FOXO1 deletion in keratinocytes 
significantly affects both normal and diabetic gingival connective tissue healing and is 
associated with regulation of mediators that stimulate angiogenesis and EMT. The goals 
of this study are: 1) to evaluate the effect of lineage specific FOXO1 deletion in 
keratinocytes during both normal and diabetic gingival connective tissue wound healing; 
2) to determine whether FOXO1 organizes keratinocyte activity to regulate angiogenesis 
during both normal and diabetic gingival connective tissue wound healing; 3) to evaluate 
the effect of lineage specific FOXO1 deletion in keratinocytes on epithelial-mesenchymal 
transition (EMT) during both normal and diabetic gingival connective tissue wound 
healing.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
Animals and induction of diabetes 
 
Animal experiments were approved by the University of Pennsylvania Institutional 
Animal Care and Use Committee. Mice with floxed Foxo1 were provided by R.A. 
DePinho (MD Anderson Cancer Center, Houston, TX) as previously described (116). 
Mice expressing Cre recombinase under the control of keratin 14 promoter (K14-Cre; 
strain Tg(KRT14-cre)1Amc/J) were obtained from the Jackson Laboratory. Lineage-
specific Foxo1 deletion was obtained by crossing these 
mice to generate experimental (K14.Cre+.Foxo1L/L) and 
control (K14.Cre-.Foxo1L/L) mice (Fig. 11). Two to five 
mice were housed per cage under standard conditions 
with a 14-h light/10-h dark cycle. All the experiments 
were performed with adult mice 10–20 weeks old. Type 
1 diabetes was induced by multiple low dose i.p. 
injections of streptozotocin (50 mg/kg; Sigma-Aldrich) in 
10 mM citrate buffer daily for 5 d. Control mice were treated identically with vehicle 
alone. The blood glucose levels were monitored after completion of multiple low dose 
streptozotocin or citrate buffer injections. Mice were considered to be hyperglycemic 
when serum glucose levels were >220 mg/dl. Experiments were performed when mice 
had been hyperglycemic for at least 10 days. 
Figure 11. Genotype results    
We tested with K14 specific 
primer instead of generic Cre 
primer. 
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For the EMT study we purchased transgenic mice having a tamoxifen inducible Cre-
mediated recombination system driven by the human keratin 14 (KRT14) promoter 
(K14CreER; strain Tg(KRT14cre/ER)20Efu/J ) from the Jackson Laboratory. This 
promoter is strongly active in dividing cells of epidermis and other stratified squamous 
epithelia. In order to characterize the recombination properties of a Cre transgenic 
mouse line, we crossed K14CreER transgenic mice with ROSA26 Cre reporter mouse 
(B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J). To induce Cre activity, we administered 
tamoxifen (5 mg per mouse per day) orally to the K14CreER-ROSA26 mice for 5 
consecutive days as described (117). Oral wound surgery was performed 1 week after 
the last administration (118).  
 
Gingival wounding experiment 
 
Mice were anaesthetized by i.p. 
administration of ketamine (80 mg/kg), 
xylazine (5 mg/kg) and acepromazine (1 
mg/kg). Full-thickness wounds were made 
in the palatal gingiva near the right first 
molar by means of a 1-mm biopsy punch 
(Accu-Punch; Electron Microscopy 
Sciences, USA) as described previously 
(119) (Fig. 12). A 1 mm wound size is 
commonly used in oral wound studies with mice. Larger oral wounds may jeopardize the 
animal’s wellbeing because of difficulty of eating. Wounds were assessed for both 4 and 
1 mm 
Incisors 
1st molar 
2nd molar  
3rd molar  
Figure 12. Gingival wound making         
1 mm full-thickness wound was made in 
the palatal gingiva near the right first molar. 
Rt 
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7 days post-wounding (n = 7-9 for each group). For The EMT study we examined 
wounds after 4, 7 and 14 days (n = 2-4 for each group). 
 
Histology 
 
Specimens were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 
24 h and decalcified in 10% EDTA solution. Wounds were bisected in caudocranial 
direction and embedded in paraffin. 4-µm paraffin sections were stained with 
hematoxylin and eosin (H&E) and Masson’s trichrome and histomorphometric analysis 
was performed with NIS-elements D image analysis software at the center of each 
lesion. Masson’s trichrome stain produces red keratin and muscle fibers, blue or green 
collagen and bone, light red or pink cytoplasm, and dark brown to black cell nuclei. 
Mature collagen fibers take deep blue color and the new collagen fibers stain light blue. 
For quantification of newly formed collagen in Masson’s trichrome-stained slides images 
were taken with a 20x objective from the middle and/or the two edges of the wound. 
Using NIS-elements software (Nikon), the intensity RGB threshold was set for the blue–
green positive color of collagen and the area of positive pixels was counted. For the 
EMT study palatal gingival tissues were harvested and embedded in OCT medium 
(Sakura Finetek USA, Inc., Torrance, CA, USA), immediately frozen on dry ice, and 
sectioned at 10-µm thickness. Samples were stained with DAPI and assessed by 
fluorescence microscopy. 
 
Immunohistochemistry in histological sections 
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Paraffin-embedded, formalin-fixed sample sections were processed for 
immunofluorescence analyses. Antigen retrieval was performed in 10 mM of citric acid, 
pH 6.0, at 120°C except for VEGFa, for which Proteinase K was used at room 
temperature for 30 minutes. Sections were incubated with primary antibody to FOXO1 
(rabbit; Santa Cruz Biotechnology, Inc.), CD31 (rabbit; Abcam), α-SMA (rabbit; Abcam), 
VEGFa (rabbit; Abcam) and Ki67 (rat; eBioscience) overnight at 4°C as well as the 
appropriate isotype-matched negative control IgG. Biotinylated secondary antibody 
(Vector Laboratories) and ABC reagent (Vector Laboratories) were then used. Tyramide 
signal amplification (Adipogen) was also used to enhance the chromogenic signal. 
Finally, Alexa Fluor 546–conjugated streptavidin (Invitrogen) and/or fluorescein avidin 
(Vector Laboratories) and DAPI-containing mounting media were used to visualize the 
staining (Sigma-Aldrich). In order to rule out the pericytes, we excluded α-SMA positive 
cells if they are morphologically associated with blood vessels. This was assisted by use 
of immunofluorescence with antibody to CD31 in adjacent slides to detect blood vessels.  
In order to further assess how keratinocytes through FOXO1 regulate connective tissue 
healing we analyzed fibroblasts/endothelial cell proliferation with an antibody to Ki67 and 
apoptosis with TUNEL assay with/without an antibody to CD31. Fibroblasts were 
identified by their typical spindle-shaped appearance. Apoptosis was quantified by 
TUNEL assay and samples were incubated at 37°C for an hour with fluorescein-12-
dUTP (Thermo Fisher Scientific) catalytically incorporated by recombinant terminal 
deoxynucleotidyl transferase (Promega). Negative controls were similarly treated with 
the omission of rTDT.  
Images were taken at 4x, 20x, and 40x magnification with a fluorescence microscope 
(ECLIPSE 90i; Nikon) with the same exposure time for experimental and negative 
control groups. Image analysis was performed using NIS Elements AR image analysis 
	  
	  
31	  
software. The number of immunopositive cells divided by the area or number of DAPI-
positive cells was used to measure the percentage of positive cells for each measured 
antibody. Mean fluorescence intensity was measured by NIS Elements AR image 
analysis software, with a maximum fluorescence intensity set at 3,000 arbitrary units to 
obtain results in the linear response range. For the EMT study we washed the samples 
with PBS and mounted with DAPI. Images were taken as previously described.  
 
Cell culture and transfection 
 
Human immortalized gingival keratinocytes (HIGK) cells were provided by Jeffrey J. 
Mans (University of Florida, Gainesville, FL), immortalized with human papilloma virus 
type 16, the E6/E7 gene and maintained in KGM-2 growth medium supplemented with 
human keratinocyte growth supplements (Lonza). Primary mouse epidermal 
keratinocytes were isolated from the neonates (0–2d) of experimental 
(K14.Cre+.Foxo1L/L) and control (K14.Cre-.Foxo1L/L) mice. In brief, mouse skin was 
collected and digested with 2.5 U/ml Dispase II (Roche) overnight at 4°C. The dermis 
was then separated from the epidermis by digesting with 0.1% trypsin and 0.02% EDTA 
in PBS for 15 min at 37°C. Keratinocytes from the epidermis were cultured in KGM-2 
growth medium containing antibiotics. All cell cultures were maintained in a 5% CO2 
humidified incubator at 37°C. Keratinocytes were passaged in KGM-2 growth media with 
supplements including standard insulin (8.6 x 10-7 M). For assays, cells were transferred 
to KGM-2 media with supplements except the insulin. ON-TARGETplus SMARTpool 
siRNAs against human FOXO1 and control siRNA (ON-TARGETplus Non-targeting 
Control Pool) were obtained from GE Healthcare and transfection was performed using 
GenMute siRNA Transfection Reagent (SignaGen Laboratories). In most transfection 
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experiments, cells were incubated for 6 h with siRNA and transfection reagent 2 d before 
assay. Cells were then rinsed and transferred back to the indicated culture media for the 
remaining incubation period.  
 
Immunofluorescence analysis in vitro 
 
Primary keratinocytes isolated from K14.Cre+.Foxo1L/L and K14.Cre-.Foxo1L/L mice and 
HIGK cells were grown on 96-well plates. HIGK cells were transfected with FOXO1 or 
scrambled siRNA. After 24 hour incubation in KBM-2 media with/without supplements 
except insulin, both primary keratinocytes and HIGK cells were fixed with 10% formalin, 
permeabilized with 0.5% Triton X-100 and incubated overnight at 4oC with primary 
antibodies to FOXO1 (rabbit; Santa Cruz Biotechnology, Inc.), VEGFa (rabbit; Santa 
Cruz Biotechnology Inc.) or negative control IgG. Primary antibody was localized with 
biotinylated secondary antibody and visualized with streptavidin-conjugated Alexa Fluor 
546. Avidin-biotin peroxidase enzyme complex (Vector Laboratories) and tyramide signal 
amplification (Adipogen, San Diego, CA, USA) were used to enhance the fluorescent 
signal. Nuclei were stained with DAPI. Images were captured with a fluorescence 
microscope (Nikon) and the mean fluorescence intensity (MFI) was determined using 
NIS Elements AR software (Nikon).  
 
Luciferase reporter assay 
 
Transient transfection with luciferase reporter constructs was performed using 
Lipofectamine3000 (Invitrogen) in 48-well plates. In brief, HIGK cells were incubated in 
culture media with/without insulin for 5 d with 5 mM d-glucose. Cells were cotransfected 
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with VEGFa luciferase reporter (provided by Dr. Keping Xie, University of Texas M. D. 
Anderson Cancer Center, Houston, TX) (120) together with pRL-TK luciferase control 
vector, FOXO1-AAA plasmid that is constitutively transported to the nucleus, pcDNA3.1 
control plasmid, scrambled or FOXO1 siRNA. 2 d after transfection, cells were lysed, 
and Firefly and Renilla luciferase activities were measured using Dual Luciferase 
Reporter Assay kit (Promega) according to the manufacturer’s instructions. Firefly 
luciferase activities were divided by Renilla activities to normalize for transfection 
efficiency. Experiments were performed three times with similar results. In some 
experiments, primary murine keratinocytes from K14.Cre-.FOXO1L/L mice in low (5 mM 
d-glucose) glucose medium were cotransfected with VEGFa luciferase reporter together 
with pRL-TK luciferase control vector, FOXO1, FOXO1-AAA plasmid and pcDNA3.1 
control plasmid. 2 days after transfection, cells were lysed and tested with the Dual 
Luciferase Reporter Assay (Promega).  
 
Microarray analysis  
 
Normal human epidermal keratinocytes (NHEK) cells were incubated in low (5 mM d-
glucose) or high (25 mM d-glucose) glucose medium for 5 days and transfected with 
FOXO1 or scrambled siRNA. Total RNA was then isolated using an RNeasy kit 
(QIAGEN). RNA profiling was performed using a GeneChIP Human Gene 1.0 ST array 
(Affymetrix). The identification of genes that were up- or down-regulated by high glucose 
and FOXO1 knockdown was defined as those that were both up-regulated (>1.3-fold) by 
high glucose and down-regulated (<0.7-fold) by FOXO1 siRNA with P < 0.05, both when 
compared with the matched control group.  
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Statistics  
 
Statistical analysis between Cre+ and Cre- groups was performed using 2-tailed 
Student’s t test. In experiments with multiple time points or treatments, differences 
between the wild type and experimental groups were determined by ANOVA with 
Scheffe's post-hoc test. Results were expressed as the mean ± SEM. P< 0.05 was 
considered statistically significant. 
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CHAPTER 3 
RESULTS 
 
3.1 To evaluate the effect of lineage specific FOXO1 deletion in keratinocytes 
during both normal and diabetic gingival connective tissue wound healing 
 
3.1.1 Keratinocyte-specific FOXO1 deletion impairs connective tissue healing in 
normoglycemic mice while showing no significant difference in diabetic mice  
 
1-mm full-thickness 
wounds were created in 
the palatal gingiva near 
the right first molar in 
experimental transgenic 
mice (K14.Cre+.Foxo1L/L) 
with keratinocyte-specific 
deletion of Foxo1 driven 
by keratin-14 Cre 
recombinase and 
littermate control 
(K14.Cre-.Foxo1L/L) mice without Foxo1 deletion. We confirmed that Foxo1 expression 
was decreased by Cre recombinase in the epithelium compared with matched control 
mice, consistent with our previous results (113). In contrast, there was little difference 
Figure 13. FOXO1 Immunofluorescence                     
demonstrating lineage-specific Foxo1 deletion in keratinocytes  
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observed in the connective tissue, demonstrating lineage-specific deletion in 
keratinocytes (Fig. 13).  
Deletion of Foxo1 in keratinocytes of nondiabetic mice delayed connective tissue healing 
(day 4, Fig. 14 A-D). The gap between the edges of connective tissue was increased by 
keratinocyte-specific FOXO1 deletion in both day 4 and 7 nondiabetic wounds (P<0.05). 
Even though both normoglycemic experimental and control mice showed the complete 
re-epithelialization on day 7, there was the incomplete bridging of the wound by 
connective tissue in experimental K14.Cre+.Foxo1L/L mice (Fig. 14 E and F, H & E). Both 
granulation tissue formation and collagen production in the normoglycemic wounds of 
experimental K14.Cre+.Foxo1L/L mice was reduced, but diabetic mice showed the similar 
results between experimental and control mice on both day 4 and day 7 wounds (Fig. 15 
A-D, Masson’s trichrome stain). Thus, keratinocyte-specific Foxo1 deletion in 
normoglycemic mice has a pronounced effect on healing of connective tissue. 
 
Figure 14. Keratinocyte-specific deletion of FOXO1 impairs gingival connective tissue 
healing responses in normoglycemic wounds. (A-C) Quantification of normoglycemic wound 
healing in H&E stained sections (day 4) including (A) wound gap, (B) area and (C) length. (D) 
Hematoxylin and eosin (H & E) staining of both normal and diabetic K14.Cre-.Foxo1L/L and 
K14.Cre+.Foxo1L/L mice wound biopsies on day 4 after wounding (10x). (E) Normoglycemic 
K14.Cre-.Foxo1L/L and K14.Cre+.Foxo1L/L mice wound biopsies on day 7. Red circles demonstrate 
the difference of connective tissue healing between the experimental and control mice. There was 
the incomplete bridging of the wound by connective tissue in experimental K14.Cre+.Foxo1L/L 
mice (10x). (F) Connective tissue gap on day 7. EPI, epithelium; CT, connective tissue; B, bone. 
Each in vivo value is the mean ± SEM for n=7-9 mice per group. *, P<0.05 versus Cre- group; #, 
P<0.05 versus matched normoglycemic control group. 
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Figure 15. Keratinocyte-specific deletion of FOXO1 decreases collagen production in 
normoglycemic wounds. (A) Old collagen fibers take deep blue color and the new collagen 
fibers stain light blue, representing mature or early collagen (20x). (B) Representative images of 
Masson's trichrome staining (10x). (C and D) Newly formed collagen on both day 4 and 7 was 
measured in Masson's trichrome stained sections. Each in vivo value is the mean ± SEM for n=7-
9 mice per group. *, P<0.05 versus Cre- group; #, P<0.05 versus matched normoglycemic control 
group. 
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3.1.2 Keratinocyte-specific FOXO1 deletion in normal wounds results in decreased 
fibroblast proliferation and increased apoptosis in vivo  
	  
The effect of keratinocyte-specific Foxo1 deletion on fibroblast numbers was assessed in 
vivo. Fibroblast density in connective tissue was reduced by 56% in normoglycemic 
wounds (day 4, P<0.05), but was similar with or without keratinocyte-specific FOXO1 
deletion in diabetic wounds (Fig. 16 A-C). Myofibroblasts are crucial for the wound 
contraction and maturation. The number of myofibroblasts was reduced 57% by FOXO1 
deletion in epithelium in normal wounds (P<0.05) but increased by 82% (Day 4) and 
28% (Day 7) in diabetic wounds (P<0.05) (Fig. 17 A-D). The differentiation of fibroblasts 
to myofibroblasts is a key event in connective tissue wound healing (121). When tissues 
are injured, fibroblasts are activated and differentiate into myofibroblasts, which contract 
and participate in healing by reducing the size of wound and secreting extracellular 
matrix (ECM) proteins. We next investigated the effect of keratinocyte-specific Foxo1 
deletion on fibroblast proliferation and apoptosis in vivo. The percentage of proliferating 
fibroblasts was measured by the number of Ki67–positive fibroblasts divided by total 
fibroblast number. Ki-67 is used as a marker for determining the growth fraction of a 
given population of cells. Ki-67 is present during all active phases of the cell cycle (G1, 
S, G2, and mitosis), but is absent from resting cells (G0). During interphase, the Ki-67 
antigen can be exclusively detected within the cell nucleus, whereas in mitosis most of 
the protein is relocated to the surface of the chromosomes. The percentage of 
proliferating fibroblasts was reduced by 68% (day 4 normal) in K14.Cre+.Foxo1L/L mice 
compared to littermate control mice (P<0.05), indicating impaired fibroblast proliferation 
with epithelial-specific FOXO1 deletion (Fig. 18 A and B). In diabetic wounds the 
percentage of proliferating fibroblasts was similar on day 4, but showed a 2.7 fold 	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Figure 16. Keratinocyte-specific deletion of FOXO1 decreases fibroblast density in 
normoglycemic wounds. (A) Representative images of Hematoxylin and eosin (H & E) staining 
of K14.Cre-.Foxo1L/L and K14.Cre+.Foxo1L/L mice wound biopsies on day 4 after wounding (40x). 
Fibroblasts were identified by their typical spindle-shaped appearance. (B and C) Fibroblast 
density in newly formed connective tissue was measured in H & E stained histologic sections. 
Each in vivo value is the mean ± SEM for n=7-9 mice per group. *, P<0.05 versus Cre- group; #, 
P<0.05 versus matched normoglycemic control group. 
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Figure 17. Keratinocyte-specific deletion of FOXO1 decreases the number of 
myofibroblasts in normoglycemic wounds but increases in diabetic wounds. (A and B) 
Representative images of α-SMA immunofluorescence (40x, day 4, normoglycemic and diabetic 
mice) (C and D) α-SMA immunofluorescence analyses of myofibroblasts in newly formed 
connective tissue. Each in vivo value is the mean ± SEM for n=7-9 mice per group. *, P<0.05 
versus Cre- group; #, P<0.05 versus matched normoglycemic control group. 
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increase in K14.Cre+.Foxo1L/L mice on day 7 (P<0.05). The percentage of apoptotic 
fibroblasts increased by 3-fold in Foxo1-deficient normoglycemic wounds compared with 
control mice (P<0.05) on day 4 but decreased by 60% in FOXO1-deficient diabetic 
wounds on day 7 (P<0.05) (Fig. 18 C and D). In addition, we observed a 53% decrease 
in keratinocyte proliferation in the normoglycemic wound epithelium of Foxo1-deleted 
mice (day 4, P<0.05) (Fig. 18 E and F).  
 
Figure 18. Keratinocyte-specific FOXO1 deletion in normal wounds reduces fibroblast 
proliferation but enhances apoptosis. (A and B) Ki67 immunofluorescence analyses of 
proliferating fibroblasts in connective tissue. Fibroblasts were identified by their typical spindle-
shaped appearance. (C and D) Apoptotic fibroblasts were measured by TUNEL staining. (E and 
F) Quantification of Ki67 immunopositive keratinocytes. Each in vivo value is the mean ± SEM for 
n=7-9 mice per group. *, P<0.05 versus Cre- group; #, P<0.05 versus matched normoglycemic 
control group. 
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3.2 To determine whether FOXO1 organizes keratinocyte activity to regulate 
angiogenesis during both normal and diabetic gingival wound healing.  
 
3.2.1 Keratinocyte-specific FOXO1 deletion impairs neovascularization in 
normoglycemic mice while showing no significant difference in diabetic mice  
 
Angiogenesis in the wound granulation tissue was compared between experimental 
(K14.Cre+.Foxo1L/L) and control (K14.Cre-.Foxo1L/L) mice based on the expression of the 
endothelial cell marker CD31 (Fig. 19 A and B). Vascular density was calculated as the 
number of CD31 immunopositive blood vessels/mm2. Foxo1 ablation in keratinocytes of 
normoglycemic mice decreased vascular density in connective tissue by 52% (day 4) 
and 44% (day 7) compared with control littermates (P < 0.05) (Fig.19 C and D). In 
contrast, keratinocyte-specific Foxo1 ablation in diabetic mice did not affect vascular 
density in experimental compared to matched control mice (P > 0.05).  
To investigate mechanisms through which FOXO1 deletion in epithelium affected 
angiogenesis during wound healing, endothelial cell proliferation and apotosis were 
assessed in vivo. Foxo1 deletion in normoglycemic mice caused a significant 40% (day 
4) and 49% (day 7) reduction in the percentage of both Ki67 and CD31–positive 
proliferating EC in wounds (P < 0.05; Fig. 19 E and F). In contrast, Foxo1 deletion in 
keratinocytes of diabetic mice did not show the significantly different results. The 
percentage of apoptotic EC is very low in our study.  
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Figure 19. Keratinocyte-specific FOXO1 deletion in normal wounds reduces vascular 
density and endothelial cell proliferation. (A and B) CD31 immunofluorescence analyses in 
newly formed connective tissue (40x, day 4, normoglycemic and diabetic mice). (C and D) 
Vascualr density in newly formed connective tissue. (E and F) Quantification of CD31 and Ki67 
double immunopositive cells for analyses of proliferating endothelial cells. Each in vivo value is 
the mean ± SEM for n=7-9 mice per group. *, P<0.05 versus Cre- group; #, P<0.05 versus 
matched normoglycemic control group. 
	  
3.2.2 The effect of keratinocyte-specific FOXO1 deletion on angiogenesis is 
mediated by VEGF-A  
 
Transfection of HIGK cells with FOXO1 siRNA significantly reduced VEGFa protein 
levels by 57% in standard glucose media (P<0.05; Fig. 20 A-C). Keratinocyte-specific 
FOXO1 deletion in vivo also significantly reduced VEGF-A protein levels by 53% (day 4, 
p<0.05) and 42% (day 7, p<0.1) in wounded epithelium from normoglycemic mice but 
had little effect on VEGF-A levels in diabetic mice (P>0.05) (Fig. 21 A-D). Surprisingly in 
normal wounds VEGF-A expression in the connective tissue was reduced by 58% (day 
4, p<0.05) and 52% (day 7, p<0.05) when FOXO1 was deleted in epithelium, indicating 
that keratinocytes play an important role in VEGF-A expression in connective tissue. In 
diabetic wounds VEGF-A expression in both epithelium and connective tissue were 
similar between experimental (K14.Cre+.Foxo1L/L) and control (K14.Cre-.Foxo1L/L) mice 
on day 4 but there was a small but significant 1.7 fold increase of VEGF-A expression in 
connective tissue on day 7 (p<0.05). This is consistent with our vascular density results. 
To determine whether FOXO1 can regulate VEGF-A transcriptional activity, we 
examined the luciferase activity of the VEGF-A reporter in HIGK and primary mouse 
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epidermal keratinocytes. The luciferase reporter analysis revealed that overexpression 
of constitutively active FOXO1 (FOXO1AAA) results in a 2.1-fold increase in VEGF-A 
transcriptional activity in HIGK cells and a 3.3-fold increase in primary mouse epidermal 
keratinocytes, whereas FOXO1 silencing produced a 20-43% decrease in VEGF-A 
promoter activity in HIGK cells (P < 0.05; Fig. 22 A-C). These results indicate that 
FOXO1 transactivates VEGF-A promoter activity and suggests that VEGF-A may be a 
downstream target of FOXO1.  
	  
	  
48	  
  
 
	  
	  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 20. FOXO1 deletion in keratinocytes reduces VEGF expression in normal glucose 
media. (A) Representative images of VEGF-A immunofluorescence in human immortalized 
gingival keratinocytes (HIGK). (B) FOXO1 mean fluorescence intensity analysis. (C) VEGF-A 
mean fluorescence intensity analysis. In vitro values represent the mean ± SEM of three 
independent experiments. *P<0.05  
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Figure 21. FOXO1 deletion in keratinocytes in normoglycemic wounds reduces VEGF 
expression in vivo. VEGF-A immunofluorescence on normoglycemic (A) and diabetic wounds 
(B) (day 4). VEGF-A mean fluorescence intensity analysis on day 4 (C) and day 7 (D). Each in 
vivo value is the mean ± SEM for n=7-9 mice per group. *, P<0.05 versus Cre- group; +, P<0.1 
versus Cre- group; #, P<0.05 versus matched normoglycemic control group. 
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Figure 22. FOXO1 transactivates VEGF expression in normal glucose media. (A-C) VEGF-A 
luciferase reporter gene analyses. FOXO1 overexpression in HIGK cells (A) and primary mouse 
epidermal keratinocytes (PMEK) (B). FOXO1 silencing in HIGK cells (C). Data show mean ± SEM 
of at least three independent experiments. *P < 0.05 
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3.3 To evaluate the effect of lineage specific FOXO1 deletion in keratinocytes on 
epithelial-mesenchymal transition (EMT) during both normal and diabetic gingival 
connective tissue wound healing.  
 
We examined K14CreER-ROSA26 mice in which keratinocytes were genetically altered 
to permanently express TdTomato with tamoxifen administration, allowing us to map the 
fate of these cells and definitively test in vivo whether EMT occurs during wound healing. 
TdTomato was strongly expressed following Cre-mediated recombination with tamoxifen 
administration. But, we did not find the reporter activity in the connective tissue indicating 
that there was no transition to typical fibroblasts or myofibroblasts with initial samples 
(n=2-4 per each group) (Fig. 23 A-E). 
 
Figure 23 DAPI stain of oral wounds of K14CreER-ROSA26 mice. (left to right) 
Negative control, day 4 experimental, day 7 experimental and day 14 experimental 
wounds. (20x)  
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 CHAPTER 4 
DISCUSSION 
 
VEGF-A is a key molecule that orchestrates the formation and function of vascular 
networks (122). It functions as an endothelial cell mitogen (123, 124), chemotactic agent 
(125), and inducer of vascular permeability (126). Unlike other angiogenic growth factors 
such as basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-
β), VEGF-A affects multiple components of the wound-healing cascade including 
angiogenesis, re-epithelialization and collagen deposition. The endothelium of the 
microvasculature exhibits several important responses to extracellular VEGF-A including 
increased endothelial proliferation and increased permeability, exerted through a change 
in endothelial cell structure and function (127, 128). Several lines of evidence indicate 
that FOXO1 deletion in keratinocytes in vivo led to deficient angiogenesis and 
substantially reduced the expression of VEGF-A during normal wound healing. In vitro 
HIGK cells with FOXO1 knockdown by siRNA substantially reduced VEGF-A expression 
and decreased VEGF-A promoter activity, and Cre recombinase deletion of Foxo1 in 
primary mouse keratinocytes reduced VEGF-A protein levels. Conversely, 
overexpression of constitutively active FOXO1 in both HIGK and primary murine 
keratinocytes significantly increased VEGF-A promoter activity in luciferase reporter 
assays. These results suggest that the avascular epidermis has the capacity to regulate 
angiogenesis by a paracrine mechanism involving the secretion of VEGF-A and FOXO1 
is needed for adequate VEGF-A expression.  
Interestingly we found that FOXO1 deletion in keratinocytes affected the VEGF-A 
expression in both epithelium and connective tissue. As a possible explanation one of 
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the major cellular components of wound granulation tissue relevant to healing and 
angiogenesis is macrophages (23, 24, 129). Macrophages in the wound tissue supply 
pro-inflammatory chemoattractants to recruit and activate additional macrophages, 
which participate in wound repair by secreting cytokines that induce angiogenesis, such 
as VEGF and TGF-β. Macrophages can also increase vascular permeability by releasing 
vasoactive substances such as vascular permeability factor (130), substance P (131), 
platelet activating factor and prostaglandins (132). Macrophage depletion during wound 
healing in mice results in decreased wound levels of TGF-β1 (27), suggesting that 
macrophages represent a major cellular source of TGF-β1 during normal wound healing 
(133). Evidence obtained in macrophage-deficient mice confirmed the essentiality of 
macrophages to the neovascularization of wounds (25, 27, 134, 135). Goren et al. 
showed that the altered expression patterns of vascular endothelial growth factor on 
macrophage reduction were associated with a disturbed neovascularization at the 
wound site (26). Leibovich et al. demonstrated that mice with non-functioning 
macrophages display retarded wound repair (134). This retarded wound repair includes 
delayed re-epithelialization, delayed neovascularization and aberrant granulation tissue 
formation (27, 135). Mirza et al. showed that macrophage depletion resulted in delayed 
re-epithelialization, decreased collagen deposition, impaired angiogenesis, and reduced 
cell proliferation associated with increased production of tumor necrosis factor (TNF)-α 
and decreased production of TGF-β1 and vascular endothelial growth factor (VEGF) 
(27). Also TGF-β1 is known for a chemoattractant for macrophages (136) and our 
previous study proved that FOXO1 regulates TGF-β1 in keratinocytes (110). However, 
most of studies still demonstrate that keratinocytes are the main producer of VEGF-A 
during wound healing (4, 9, 65). Brown et al. revealed that greatly increased amounts of 
vascular permeability factor (VPF) mRNA were expressed by keratinocytes, initially 
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those at the wound edge and at later intervals, keratinocytes that migrated to cover the 
wound surfaces; occasional mononuclear cells also expressed VPF mRNA (4). Rossiter 
et al. performed wound-healing studies in mice with VEGF-A-deficient keratinocytes and 
showed that the wounds contained fewer blood vessels beneath the epidermis and 
healed more slowly (65).  
The contribution of VEGF-A to overall wound closure and epidermal repair has been 
examined extensively in animal studies (1). VEGF-A, which is normally expressed at low 
levels by epidermal keratinocytes, is up-regulated in these cells in injured skin (4). 
Studies in human wounds and animal models have indicated that VEGF-A is produced 
by keratinocytes early and later stages in the wound-healing process (64, 137). 
Activated fibroblasts, mast cells, and macrophages also express VEGF-A in injured skin 
(4, 138, 139). Traditionally, VEGF-A produced by epidermal keratinocytes was thought 
to act in a paracrine manner, stimulating endothelial cells in blood vessels within the 
underlying dermis (1). The expression of the flt-1 receptor for VEGF-A is up-regulated in 
the sprouting blood vessels at the wound edge and in endothelial cells of the granulation 
tissue (54). However VEGF-A has been shown to stimulate keratinocyte migration and 
collagen production via fibroblasts (53). Functional VEGFRs have been recently 
identified on keratinocytes (72-75), which suggests the possibility of autocrine VEGF-A 
signaling in keratinocytes as well as direct effects of VEGF-A derived from other cellular 
sources on keratinocytes. Several studies have also shown that VEGF-A enhances 
macrophage recruitment in vivo (140-143). Hong et al. demonstrated an increase in the 
density of macrophages has been observed in wounds created in transgenic mice that 
overexpress VEGF-A in the epidermis, suggesting that VEGF-A plays a role in recruiting 
macrophages to damaged skin (81). Reducing VEGF-A activity by treating with 
neutralizing antibodies or small molecule inhibitors of VEGF-A signaling or conditional 
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genetic deletion of VEGF-A lead to delayed healing (65, 72, 144, 145). Additionally, 
topical treatment with neutralizing antibodies to VEGFR-1 results in reduced re-
epithelialization rates (72). Both keratinocyte-derived and myeloid cell–derived VEGF-A 
have been shown to affect some components of the repair process (65, 137, 144). For 
example, delayed wound closure, reduced vessel density, and decreased granulation 
tissue formation have been reported in mice lacking VEGF-A in myeloid cells (137, 144), 
and delayed wound closure and reduced vessel density have been reported in mice 
lacking VEGF-A in keratinocytes (65). Direct and indirect evidences implicate VEGF-A 
as a significant factor in wound healing immediately after injury. 
Angiogenesis, the sprouting of new capillaries from the preexistent blood vessels, is of 
central importance in many biological processes, including embryonic vascular 
development and differentiation, wound healing, and organ regeneration (115, 146, 147). 
In addition, angiogenesis plays a major role in pathological conditions such as diabetic 
retinopathy, rheumatoid arthritis, psoriasis, cardiovascular diseases, tumor growth, and 
metastasis (148, 149). During angiogenesis, endothelial cells migrate, proliferate, 
organize into tube-like structures, and play an active role in tissue remodeling. In our 
study FOXO1 deletion in keratinocytes reduced endothelial cells proliferation in vivo. 
Endothelial cell apoptosis in vivo can be evaluated by one or more of several techniques, 
including immunofluorescence staining for endothelial specific markers, detection of 
DNA strand breaks by terminal deoxynucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL), assay for caspase activation and measurement of phosphatidyl serine 
exposure by annexin V binding (150-152). Morphologic changes characteristic of 
apoptosis were also identified: cell shrinkage, nuclear and cytoplasmic condensation, 
and cellular budding into "apoptotic bodies”. In our study we could find TUNEL positive 
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cells but observe very little endothelial cell apoptosis. Generally apoptotic cell death and 
in particular endothelial cell apoptosis may be difficult to observe in vivo as apoptotic 
cells are rapidly phagocytosed and their digestion can be completed within 60 min (153, 
154). Notably, endothelial cells can engulf apoptotic cells or apoptotic bodies (155, 156). 
Moreover, apoptotic endothelial cells may detach from the vessel wall into the circulation. 
Another possible reason is the time points for endothelial cell apoptosis. At the end of 
the proliferative phase fibroblasts start to undergo apoptosis. Endothelial cells and 
remaining fibroblasts disappear upon the completion of wound maturation (11). 
Desmouliere et al. examined apoptotic patterns in cells in open wounds created in rats 
(157). They found that apoptosis in myofibroblasts began on day 12, peaked at 20 d and 
resolved by 60 d suggesting that myofibroblast apoptosis begins about the same time as 
wound closure. Apoptosis patterns in the cells of the neovasculature similarly started at 
around 12 d and had maximal expression of apoptosis between 16 and 25 d. The 
parallel apoptosis patterns of fibroblasts and endothelial cells suggest that there is a 
coordinated decrease in cellularity with wound maturation that may involve cell to cell 
communication. In our study we used both day 4 and 7, when wound closure starts but it 
may be early for the endothelial cell apoptosis.  
In our study we found that FOXO1 deletion in epithelium led to impaired connective 
tissue healing that included decreased formation of new connective tissue in normal 
mice. Fibroblast numbers and proliferation were both reduced when FOXO1 was deleted 
in keratinocytes consistent with impaired production of extracellular matrix. In addition 
keratinocyte-specific FOXO1 deletion led to reduced myofibroblast numbers. Our results 
agree with the previous papers (110). As a possible mechanism TGF-β1 and connective 
tissue growth factor (CTGF) are the key regulators of connective tissue healing 
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prompting the expression of ECM proteins such as collagen and initiating granulation 
tissue formation (158). TGF-β stimulates the expression of CTGF, which is thought to be 
responsible for many of the pro-fibrotic properties of TGF-β, particularly in the promotion 
of fibroblast proliferation and ECM production (159, 160). CTGF plays a physiological 
role in early wound healing (161). Previous studies in our lab found that TGF-β1 and 
CTGF expression in both epithelium and connective tissue were decreased by 
keratinocyte-specific deletion of FOXO1 during wound repair (submitted). Interestingly, 
they found that the same deletion of FOXO1 in diabetic wounds had the opposite effect, 
significantly improving the healing response (111, 113). However in our study we found 
that diabetic wound healing was impaired, compared with normal mice group but there 
was no significant difference between diabetic experimental and control groups. A 
possible explanation for those similar results is a relatively significant commensal flora in 
oral cavity that might mask the effect of FOXO1 deletion in keratinocytes. The bacteria of 
the oral cavity have the potential to alter the wound healing process by interacting with 
keratinocytes (162). Treatment with antibiotics may significantly diminish the persistent 
inflammatory infiltrate and improve healing in the diabetic mice (163). 
Although EMT has been mentioned sporadically in the literature as an important aspect 
of wound healing, it is still unknown whether EMT occurs during cutaneous wound 
healing (164, 165). EMT was originally described as an important cellular programming 
that orchestrates formation of mesoderm during gastrulation (83, 166). In last decade 
accumulated evidence has uncovered EMT in many chronic diseases such as cancer 
progression and fibrotic diseases. Generally the purpose of EMT is believed to mobilize 
epithelial cells into motility or invasion through loss of cell-adhesion and polarity and 
simultaneous gain of mesenchymal phenotype. TGF-β is the key cytokine involved in 
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many elements of wound healing, including the induction of EMT via many pathways. 
Previous studies in our lab found that FOXO1 regulates TGF-β, which is one of the 
predominant factors that stimulate EMT, in keratinocytes during wound healing. 
Therefore we assumed that EMT occurred and it could be regulated by FOXO1. 
However, we did not observe trans-differentiation of keratinocytes into typical fibroblasts 
or myofibroblasts with lineage tracing in transgenic mice.  
In summary, in this study we found that keratinocyte-specific deletion of FOXO1 
interfered with normal gingival connective tissue healing by decreasing granulation 
tissue formation and angiogenesis, which were mediated by VEGF-A. In particular this is 
the first evidence that avascular epithelium regulates angiogenesis involving the VEGF-
A secretion mediated by FOXO1. 
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